StockNews.com Upgrades Koninklijke Philips (NYSE:PHG) to “Buy”

Koninklijke Philips (NYSE:PHG) was upgraded by investment analysts at StockNews.com from a “hold” rating to a “buy” rating in a research note issued on Thursday.

A number of other equities analysts also recently commented on the stock. Jefferies Financial Group upgraded shares of Koninklijke Philips from an “underperform” rating to a “hold” rating in a research report on Tuesday, October 29th. UBS Group raised shares of Koninklijke Philips from a “neutral” rating to a “buy” rating in a report on Thursday. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, Koninklijke Philips has a consensus rating of “Moderate Buy”.

Koninklijke Philips Price Performance

Shares of NYSE:PHG opened at $25.53 on Thursday. The company has a debt-to-equity ratio of 0.60, a quick ratio of 0.74 and a current ratio of 1.16. Koninklijke Philips has a one year low of $19.75 and a one year high of $32.91. The company has a 50-day simple moving average of $26.25 and a 200-day simple moving average of $28.14. The stock has a market capitalization of $24.00 billion, a price-to-earnings ratio of -30.40, a PEG ratio of 0.82 and a beta of 0.77.

Koninklijke Philips (NYSE:PHG) last posted its quarterly earnings data on Wednesday, February 19th. The technology company reported $0.54 EPS for the quarter, missing the consensus estimate of $0.55 by ($0.01). Koninklijke Philips had a negative net margin of 3.88% and a positive return on equity of 10.94%. The company had revenue of $5.38 billion for the quarter, compared to analysts’ expectations of $5.10 billion. On average, analysts predict that Koninklijke Philips will post 1.63 EPS for the current year.

Institutional Investors Weigh In On Koninklijke Philips

Institutional investors have recently made changes to their positions in the stock. Creative Planning lifted its stake in shares of Koninklijke Philips by 39.3% in the third quarter. Creative Planning now owns 84,263 shares of the technology company’s stock valued at $2,757,000 after purchasing an additional 23,768 shares during the period. Blue Trust Inc. lifted its position in shares of Koninklijke Philips by 223.8% during the 3rd quarter. Blue Trust Inc. now owns 11,982 shares of the technology company’s stock valued at $392,000 after acquiring an additional 8,282 shares during the period. OLD National Bancorp IN purchased a new stake in shares of Koninklijke Philips during the 3rd quarter worth approximately $202,000. Allspring Global Investments Holdings LLC grew its holdings in shares of Koninklijke Philips by 29.9% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 7,347 shares of the technology company’s stock worth $240,000 after acquiring an additional 1,690 shares during the period. Finally, Signaturefd LLC increased its stake in Koninklijke Philips by 6.7% in the 3rd quarter. Signaturefd LLC now owns 28,401 shares of the technology company’s stock valued at $929,000 after purchasing an additional 1,789 shares in the last quarter. 13.67% of the stock is currently owned by hedge funds and other institutional investors.

Koninklijke Philips Company Profile

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. The company operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. It also provides diagnostic imaging solutions, includes magnetic resonance imaging, X-ray systems, and computed tomography (CT) systems and software comprising detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; integrated interventional systems, and interventional diagnostic and therapeutic devices to treat coronary artery and peripheral vascular disease.